Sun, Feb 1, 2015, 4:12 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Accuray Incorporated (ARAY) Message Board

rolo4477 4 posts  |  Last Activity: Jan 28, 2015 9:38 PM Member since: Apr 1, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • rolo4477 by rolo4477 Jan 28, 2015 9:38 PM Flag

    For better or worse, the coming week will witness increased attention to MSON with the quarterly report due on Wednesday, February 4. It is interesting to note that Schwab has once again rated MSON with it second highest level of "B" which indicates a "Buy" or "Outperform." Reuters continues to give MSON its highest score with its "Buy" rating. Earnings estimates I was able to find suggest 30 cents for the fiscal year June '15 and 52 cents for the fiscal year June '16. My guess is that accumulation of the stock has been underway for a good part of the last year. We will soon know whether MSON takes off from its current level - or not. It all depends on the market perceiving that MSON's medical devices are gaining increased acceptance.

  • rolo4477 rolo4477 Dec 7, 2014 10:03 AM Flag

    March 22, 2007 ???? Are you serious? Don't you realize that is over seven years ago and MSON is no longer interested in Hifu?? If you are still interested in Hifu, get off this board and move to EDAP - if you think it is worth the effort.

  • rolo4477 rolo4477 Dec 2, 2014 9:54 AM Flag

    It appears that posters who have been reporting on Sonathern and EDAP on the MSON board are totally lost. Please get your companies straight. EDAP works with Sonathern. MSON does not. It is doing just fine with its bone cutter, debrider and aspirator.

  • rolo4477 by rolo4477 Nov 14, 2014 2:51 PM Flag

    Obviously, there is lots going on in the market for MSON shares. Volume, which has been quiescent for the past several years, has ballooned during the last few quarters. The price doubled from gyrating around 6 during the first half of the year to the current fluctuation around 12. Very curiously, the ratings of Schwab and Reuters, which I reported recently at "A" and "Buy", respectively, are now "no rating" and "Hold." I can not explain the Schwab action and can only surmise that Reuters may have been less than impressed that MSON did not report blowout earnings in the last quarter although nearly all metrics were highly favorable. Additionally, the market for MSON's bone scalpel and wound debrider seems to be expanding as more medical doctors report favorable results. All this leads me to believe that the price action of the last few weeks reflects two factors: First, a desire by some to take profits after the stock more than doubled. Secondly, continued accumulation by knowledgeable investors who see a bright future for MSON from growth in revenues and eventually earnings and from the possibility of a buyout.

7.37-0.02(-0.27%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.